Marina Kremyanskaya, MD, PhD, Icahn School of Medicine at Mount Sinai, New York, NY, explains the mechanism of action of rusfertide and summarizes the results of the Phase II REVIVE trial (NCT04057040). The REVIVE trial included patients with polycythemia vera (PV) requiring phlebotomies with or without cytoreductive therapy. The trial reported that patients treated with rusfertide no longer needed phlebotomies and achieved good hematocrit and ferritin control. In addition, patients reported an improvement in total symptom scores. A Phase III trial (VERIFY - N CT05210790) is currently underway. This interview took place virtually.

свернуть